Hiroki Hayashi

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial

Athol U. Wells, Kevin R. Flaherty, Kevin K. Brown et al. · The Lancet Respiratory Medicine · 2020 · 522 citations · Full text

Inbuild Trial, Parallel-group Trial, Advanced Lung Disease +5

Distinct roles of resident and nonresident macrophages in nonischemic cardiomyopathy

Xudong Liao, Yuyan Shen, Rongli Zhang et al. · Proceedings of the National Academy of Sciences · 2018 · 185 citations · Full text

Convergence of G Protein–Coupled Receptor and S-Nitrosylation Signaling Determines the Outcome to Cardiac Ischemic Injury

Z. Maggie Huang, Erhe Gao, Fábio V. Fonseca et al. · Science Signaling · 2013 · 104 citations · Full text

Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study

Toby M. Maher, Susanne Stowasser, Yasuhiko Nishioka et al. · The Lancet Respiratory Medicine · 2019 · 96 citations · Full text

Fibrosis, Extracellular Matrix Turnover, Inflammatory Lung Disease +7

Importance of Vital Signs to the Early Diagnosis and Severity of Sepsis: Association between Vital Signs and Sequential Organ Failure Assessment Score in Patients with Sepsis

Tsuneaki Kenzaka, Masanobu Okayama, Shigehiro Kuroki et al. · Internal Medicine · 2012 · 87 citations · Full text